Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts

Journal of Rheumatology

Volumn 23, Issue 1, 1996, Pages 24-31

  Martel Pelletier, Johanne ^a,e   Mineau, François ^a   Tardif, Ginette ^a   Fernandes, Julio C ^b   Ranger, Pierre ^c   Loose, Leland ^d   Pelletier, Jean Pierre ^e  

^a Department of Medicine ^*  (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d PFIZER INC   (United States)

^e NOTRE DAME HOSPITAL   (Canada)

Author keywords

DMARD; Interleukin 1 receptor; NSAID; Osteoarthritis; Rheumatoid arthritis; Synovial fibroblasts; Tenidap

Indexed keywords

COLLAGENASE; DICLOFENAC; HYDROXYCHLOROQUINE; INTERLEUKIN 1 RECEPTOR; TENIDAP;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; BLOTTING, NORTHERN; CELLS, CULTURED; COLLAGENASES; DICLOFENAC; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; HYDROXYCHLOROQUINE; INDOLES; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-1; SYNOVIAL MEMBRANE; TIME FACTORS;

EID: 0030047295     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gravallese EM, Darling JM, Ladd AL, Katz KN, Glimcher LH: In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076-84.
2. McCachren SS: Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum 1991;34:1085-93.
3. Pelletier JP, Faure MP, DiBattista JA, Wilhelm S, Visco D, Martel-Pelletier J: Coordinate synthesis of stromelysin, interleukin-1 and oncogene proteins in experimental osteoarthritis An immunohistochemical study. Am J Pathol 1993;142:95-105.
4. Hopkins SJ, Humphreys M, Jayson MIV: Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 1988;72:422-7.
5. Westacott CI, Whicker JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA: Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 1990;49:679-81.
6. Pelletier JP, McCollum R, Cloutier JM, Martel-Pelletier J: Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol 1995;(suppl 43)22:109-14.
7. Martel-Pelletier J, McCollum R, DiBattista JA, et al: The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Arthritis Rheum 1992;35:530-40
8. Sadouk M, Pelletier JP, Tardif G, Kiansa K, Cloutier JM, Martel-Pelletier J: Human synovial fibroblasts coexpress interleukin-1 receptor type I and type II mRNA: The enhanced binding of interleukin-1 in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest 1995;73:347-55
9. Pelletier JP, McCollum R, DiBattista JA, Loose LD, Cloutier JM, Martel-Pelletier J: Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 1993;36:1517-27.
10. Altman R, Asch E, Bloch D, et al: Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 1986;29:1039-49.
11. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. 1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts; mediation by cyclic-AMP-signalling pathway Lab Invest 1994;71:270-8.
13. McPherson GA. A practical computer-based approach to the analysis of radioligand binding experiments. Comput Methods Programs Biomed 1983;17:107-13.
14. Spriggs MK, Lioubin PJ, Slack J, et al: Induction of an interleukin-1 receptor (IL-1R) on monocytic cells. Evidence that the receptor is not encoded by a T cell-type IL-1R. J Biol Chem 1990;265:22499-505.
15. Aiba H, Adhya S, de Combrugghe B: Evidence for two functional gal promoters in intact Escherichia coli cells. J Biol Chem 1981;256:11905-10.
16. Ounissi-Benkalha H, Pelletier JP, Tardif G, et al: In vitro effects of two antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from rheumatoid arthritic patients. J Rheumatol 1996;23:16-23.
17. Sims JE, Acres RB, Grubin CE, et al: Cloning the interleukin 1 receptor from human cells. Proc Natl Acad Sci USA 1989;86:8946-50.
18. Tso JY, Sun XH, Kao TH, Reece KS, Wu R: Isolation and characterization of rat and human glyceraldehyde-3 phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucleic Acids Res 1985;13:2485-502.
19. Sims JE, Gayle MA, Slack JL, et al: Interleukin-1 signalling occurs exclusively via the type I receptor. Immunology 1993;90:6155-9.
20. Katz P, Borger AP, Loose LD: Evaluation of CP-66, 248 [5-chloro-2, 3-dihydro-2-oxo-3(2-thienylcarbonyl) - indole-1-carboxamide] in rheumatoid arthritis (abstr). Arthritis Rheum 1988;(suppl)31:S52.
21. Davis JS, Loose LD, Borger AP: Clinical efficacy of CP-66, 248 [5-chloro-2, 3-dihydro-2 oxo-3(2-thienylcarbonyl) - indole-1-carboxamide] in osteoarthritis (abstr). Arthritis Rheum 1988;(suppl)31:S72.
22. Akohoshi T, Oppenheim JJ, Matsushima K: Interleukin 1 stimulates its own receptor expression on human fibroblasts through the endogenous production of prostaglandin(s). J Clin Invest 1988;82:1219-24.
23. Lau CS, Belch JJF: The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-lipoxygenase inhibitor. Mediat Inflamm 1992;1:141-3.
24. McCollum R, Martel-Pelletier J, DiBattista JA, Pelletier JP: Regulation of interleukin-1 receptors in human articular chondrocytes. J Rheumatol 1991;(suppl 27)18:85-8.
25. Bryant LR, DesRosier K, Carpenter M: Hydroxychloroquine in the treatment of erosive osteoarthritis (abstr). Arthritis Rheum 1994;(suppl)37:S241.
26. Krogstad DJ, Schlesinger PH: Acid-vesicle function, intracellular pathogens and the action of chloroquine against plasmodium falciparum. N Engl J Med 1987;317:542-9.
27. Hurst NF, French JK, Gorjatschko L, Betts WH: Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxyde release. J Rheumatol 1988;15:23-7.
28. Blackburn WD Jr, Prupas HM, Silverfield JC, et al: Tenidap in rheumatoid arthritis: A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum 1995;38:1447-56.
29. Fernandes JC, Martel-Pelletier J, Otterness IG, et al: Effects of tenidap on canine experimental osteoarthritis. I. Morphological analysis and metalloprotease activity. Arthritis Rheum 1995;38:1290-303.
30. Sabiston CP, Adams PE: Production of catabolin by synovium from an experimental model of osteoarthritis. J Orthop Res 1989;7:519-29.